clinical trial · NCT07379827
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
Bristol-Myers Squibb·—·recruiting·n = 1,500
SchizophreniaXanomeline and trospium chloride (KarXT)
brief summary
The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United States
started
Feb 26, 2026
primary completion
Jun 20, 2028
completion
Jun 20, 2028
last updated
Apr 30, 2026
official title
Effectiveness and Adverse-effect Switch Evaluation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol